Log In

 
Company : 1abtik ag 
Monday, October 26, 2015 6:15PM IST (12:45PM GMT)
 
(BW)(1ABTIK-AG)
1abtik ag Founded to Fight Sepsis with Novel Antibody Therapeutics
Hünenberg, Switzerland

The 1abtik ag was recently founded with the sole focus to develop a game-changing antibody-based therapy for sepsis. 1abtik has now entered the financing phase for the drug development process ranging from the identification of lead compounds to running clinical studies including phase 2.

 

Sepsis is a disease with a confirmed very high unmet medical need that may affect any person. It often starts with unspectacular, mostly bacterial but also viral, fungal or parasite infections. However, it then seizes the entire body with a very high rate of mortality of up to 30% - 80%, depending on the severity. Close to 20mio cases of sepsis are assumed worldwide per year. The average population mortality rate related to this devastating inflammation is about 60-80 per 100'000. Moreover, up to 50% of the survivors suffer from the post-sepsis syndrome (PSS). World-wide, sepsis is one of the most expensive diseases requiring intensive care unit and emergency room settings.

 

Currently, there are no approved sepsis-specific drugs available.

 

1abtik now sets out to provide novel, potent antibody drugs required to lead such program to success. 1abtik is uniquely positioned for this purpose by planning to integrate unappreciated latest scientific data and disease target molecules with highest potency, tailor-made antibodies and in-depth know-how in the field. Past efforts to fight sepsis could neither profit from the recent scientific progress nor from the significant further development of high-end therapeutic antibodies.

 

For more information and details, please check www.1abtik.com and/or address fight.sepsis@1abtik.com

 

DISCLAIMER

 

This communication contains certain forward-looking statements, relating to 1abtik's business, general discussions of strategy and plans or intentions of 1abtik. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the results of operations, financial condition, performance, or achievements, or industry results of 1abtik to be materially different from any strategy or plans or future results expressed or implied by such forward-looking statements.

 

+++++ Additional features:

 

Document: http://n.equitystory.com/c/fncls.ssp?u=IXNRCBNRGG

 

Document title: 1abtik ag

 

403113 26.10.2015

 

 

 
For News Release background on 1abtik ag click here
 
Media Contact Details
CONTACTS : 1abtik ag Titus Kretzschmar, PhD Founder and CEO titus.kretzschmar@1abtik.com
 
 
Submit your press release
Similar News

04/01/2018 6:21PM

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

Boehringer Ingelheim announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in ...

No Image

22/12/2017 11:30AM

Denis DELVAL is Appointed CEO of LFB SA

On December 20th, a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of ...